Abstract:Background: Neurofilament light chain protein (NfL) in cerebrospinal fluid (CSF) reflects the severity of neurodegeneration, with its altered concentrations discovered in Parkinson's disease (PD) and Parkinson's disease dementia (PD-D). Objective: To determine whether CSF NfL, a promising biomarker of neuronal/axonal damage, can be used to monitor cognitive progression in de novo Parkinson's disease and predict future cognitive decline. Methods: A total of 259 people were recruited in this study, including 85 healthy controls (HC) and 174 neonatal PD patients from the Parkinson's Progression Markers Initiative (PPMI). Multiple linear regression and linear mixed effects models were used to examine the associations of baseline/longitudinal CSF NfL with cognitive decline and other CSF biomarkers. Kaplan–Meier analysis and log-rank test were used to compare the cumulative probability risk of cognition progression during the follow-up. Multivariate cox regression was used to detect cognitive progression in de novo PD. Results: We found PD patients with mild cognitive impairment (PD-MCI) was higher than with normal cognition (PD-NC) in terms of CSF NfL baseline levels ( p = 0.003) and longitudinal increase rate ( p = 0.034). Both baseline CSF NfL and its rate of change predicted measurable cognitive decline in de novo PD (MoCA, β = −0.010, p = 0.011; β = −0.0002, p < 0.001, respectively). The predictive effects in de novo PD patients aged >65, male, ill-educated (<13 years) and without carrying Apolipoprotein E ε4 ( APOE ε4 ) seemed to be more obvious and reflected in more domains investigated. We also observed that CSF NfL levels predicted progression in de novo PD patients with different cognitive diagnosis and amyloid status. After an average follow-up of 6.66 ± 2.54 years, higher concentration above the median of baseline CSF NfL was associated with a future high risk of PD with dementia (adjusted HR 2.82, 95% CI: 1.11–7.20, p = 0.030). Conclusion: Our results indicated that CSF NfL is a promising prognostic predictor of PD, and its concentration and dynamics can monitor the severity and progression of cognitive decline in de novo PD patients.

Serum neurofilament light at diagnosis: a prognostic indicator for accelerated disease progression in Parkinson's Disease

Serum NFL levels predict progression of motor impairment and reduction in putamen dopamine transporter binding ratios in de novo Parkinson's disease: An 8-year longitudinal study.

Role of Serum NFL in Parkinson's Disease: Evolution, Diagnosis, and Prognosis

Relationship between plasma NFL and disease progression in Parkinson's disease: a prospective cohort study

Relationship Between Plasma NFL and Disease Progression in Parkinson’s Disease: a Prospective Cohort Study

Serum Neurofilament Dynamics Predicts Cognitive Progression in De Novo Parkinson's Disease.

Predictive value of serum neurofilament light chain for cognitive impairment in Parkinson's disease

Evaluation of plasma levels of NFL, GFAP, UCHL1 and tau as Parkinson's disease biomarkers using multiplexed single molecule counting

Serum neurofilament indicates accelerated neurodegeneration and predicts mortality in late-stage Parkinson’s disease

Cerebrospinal fluid neurofilament dynamic profiles predict cognitive progression in individuals with de novo Parkinson's disease

Levels of plasma neurofilament light chain and cognitive function in patients with Alzheimer or Parkinson disease

Plasma NfL, GFAP, amyloid, and p-tau species as Prognostic biomarkers in Parkinson's disease

Neurofilament Light Chain Plasma Concentration Predicts Neurodegeneration and Clinical Progression in Nondemented Elderly Adults

Neurofilament Light Chain in Cerebrospinal Fluid and Blood As a Biomarker for Neurodegenerative Diseases: A Systematic Review and Meta-Analysis.

Neurofilament light chain in serum for the diagnosis of amyotrophic lateral sclerosis

Cerebrospinal Fluid Α-Synuclein Predicts Cognitive Decline in Parkinson Disease Progression in the DATATOP Cohort.

Central Nervous System-Derived Exosomal Alpha-Synuclein in Serum May Be a Biomarker in Parkinson's Disease.

Relationship between increased serum neurofilament light chain and glial fibrillary acidic protein levels with non‐motor symptoms in patients with Parkinson's disease

P3-435: plasma neurofilament light as a measure of neurodegeneration for nondemented individuals

Neurofilament Light Chain Predicts Disease Severity and Progression in Multiple System Atrophy.

Peripheral Neurofilament Light (NFL) Chain Level Predicts the Two‐year Outcome of Amnestic Mild Cognitive Impairment in Chinese Han Population